Acute GvHD risk assignment algorithms that can be used in preemption for aGvHD
| . | Time measured . | Components . | Validated . | Reference(s) . |
|---|---|---|---|---|
| MAGIC | Day 7 | ST2, Reg3alpha | Yes | 1,2 |
| aGvHD MS-17 | 14 days before onset of aGvHD | Urine proteome—identified proteins: collagen a-1(II) chain AAc; collagen a-1 (XXII) chain; serum albumin, N-term; collagen a-2(I) chain; P-2-microglobulin; collagen a-2(I) chain; collagen a-2(I) chain; CD99 antigen; collagen a-1 (I) chain | Yes | 7,8 |
| GITMO Prediction of TRM | Day 7 | Serum cholinesterase, total protein, blood urea nitrogen, c glutamyl transferase, donor type and cell dose | Yes | 9 |
| . | Time measured . | Components . | Validated . | Reference(s) . |
|---|---|---|---|---|
| MAGIC | Day 7 | ST2, Reg3alpha | Yes | 1,2 |
| aGvHD MS-17 | 14 days before onset of aGvHD | Urine proteome—identified proteins: collagen a-1(II) chain AAc; collagen a-1 (XXII) chain; serum albumin, N-term; collagen a-2(I) chain; P-2-microglobulin; collagen a-2(I) chain; collagen a-2(I) chain; CD99 antigen; collagen a-1 (I) chain | Yes | 7,8 |
| GITMO Prediction of TRM | Day 7 | Serum cholinesterase, total protein, blood urea nitrogen, c glutamyl transferase, donor type and cell dose | Yes | 9 |
TRM, transplant related mortality.